Program
NTB003
A development code.
Its studies are mostly in Graves Ophthalmopathy, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 22 open or running | phase 2since Feb 22, 2026 | Aug 18, 2025 | May 31, 2027phase 2 · NCT07462130 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2025First study: phase 1 study in TEDFirst studyNCT07182552 · 40 planned · China
- Feb 22, 2026Phase 2 study in Graves OphthalmopathyPhase 2 reachedNCT07462130 · 74 planned
Ahead
- May 31, 2027Primary completion: phase 2 study in Graves OphthalmopathyNCT07462130
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07462130Graves Ophthalmopathy | 2 | Not yet recruiting | May 31, 2027 | 74 |
| NCT07182552TED · China | 1 | By invitation | Feb 23, 2026 | 40 |
How it is read
Names in the registry
- “NTB003”, 4 entries
Codes read as this program: NTB003.
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.